Question 1

What is Plinabulin?

Accepted Answer

Plinabulin is a Other.

Question 2

How often does Plinabulin appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was Plinabulin first tracked by Ergen?

Accepted Answer

First tracked on Apr 22, 2026.

Question 4

When was Plinabulin last mentioned in news?

Accepted Answer

Last active on Apr 22, 2026.

Question 5

What is Plinabulin's current news sentiment?

Accepted Answer

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Plinabulin in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Plinabulin?

Accepted Answer

BeyondSpring Plinabulin Enhances ADC Efficacy (Apr 22, 2026, 6 articles).

Question 8

How did the "BeyondSpring Plinabulin Enhances ADC Efficacy" event impact Plinabulin?

Accepted Answer

Plinabulin is BeyondSpring's lead asset, a late-stage Phase 3 anticancer agent. New preclinical data demonstrates its potential to improve the efficacy and tolerability of Antibody-drug conjugates (ADCs) by enhancing anticancer activity, improving tolerability, and activating the immune system.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.